PROM1 and ovarian carcinoma: Addressing this hypothesis, CPI-613 treatment significantly decreased CSC frequency, expressed as CD133+/CD117+ cells, in five ovarian cancer cell lines and additionally impaired cell viability and sphere-forming capacity.